Welcome To Today’s Webinar

Thanks for joining us!
We’ll get started in a few minutes

Today’s Topic:

Draft Guidances on Transition Plans for Medical Devices:
(1) Devices That Fall within Enforcement Policies Issued During the COVID-19 Public Health Emergency and
(2) Devices Issued Emergency Use Authorizations

February 22, 2022
COVID-19 Transition Policy for Devices

Jacqueline Gertz, PhD
Policy Analyst
Clinical and Scientific Policy Staff
Office of Product Evaluation and Quality (OPEQ)

Joshua Silverstein, PhD
Policy Analyst
Regulation, Policy and Guidance Staff
Office of Product Evaluation and Quality (OPEQ)

Eli Tomar, JD
Associate Director
Office of Policy

Center for Devices and Radiological Health
U.S. Food and Drug Administration
COVID-19 Transition Policy for Devices

Jacqueline Gertz, PhD
Policy Analyst
Clinical and Scientific Policy Staff
Office of Product Evaluation and Quality (OPEQ)
Center for Devices and Radiological Health
U.S. Food and Drug Administration
Draft Guidances

- Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency

- Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency

- Referred to as “Transition Guidances” in this presentation
Learning Objectives

1. Describe background of COVID-19 public health emergency (PHE) that relates to these draft guidances

2. Review scope of draft guidances, including proposed timeframes for FDA and stakeholder actions

3. Identify how to submit comments to public dockets
Background
Questions addressed by the guidances:

• Why is FDA issuing these guidances now, while the COVID-19 pandemic is ongoing?
• What actions should I take if I do or don’t plan to distribute my devices after the relevant EUA declaration is terminated or the PHE expires?
• What important milestones should I know about during the transition process?

The draft guidances are:

• Not for implementation at this time
• Available for public comment
Background

PHE and EUA declarations

- Declaration of public health emergency (PHE) by HHS Secretary, first on January 31, 2020, most recently renewed January 14, 2022
- Three EUA declarations in 2020 for in vitro diagnostics, for respiratory protective devices, and for devices, including alternative products used as devices, under section 564 of Federal Food, Drug, and Cosmetic Act (FD&C Act)

EUAs

- FDA continues to review requests for and issue EUAs for devices
- An EUA remains in effect for the duration of the relevant EUA declaration, unless FDA chooses to revoke the EUA, applying the statutory criteria for revocation (section 564 of the FD&C Act)
- Over 900 EUAs have been issued

Enforcement policies

- FDA issued 28 guidance documents describing enforcement policies to support the COVID-19 response
- Guidances state that they are intended to remain in effect only for the duration of the COVID-19 PHE
Background

Given magnitude of COVID-19 PHE, FDA recognizes continued flexibility, while still providing necessary oversight, will be appropriate to facilitate orderly and transparent transition back to normal operations.

Unique considerations presented by COVID-19 PHE, including manufacturing of devices by non-traditional manufacturers and use of capital or reusable equipment under an EUA.

FDA developed two guidances to describe transition plan to help avoid disruption in device supply and ensure that devices meet applicable requirements after transition period.

FDA issued these draft guidances to obtain feedback from all interested stakeholders before we finalize these policies.
Transition Guidances: Scope and Timeframes
Transition is proposed in two companion guidance documents:

- Guidance transition guidance (319 PHE declaration)
- EUA transition guidance (564 EUA declarations)
Scope

EUA transition guidance

• Devices with EUAs issued on basis of a COVID-19 EUA declaration
• Does not apply to:
  • Devices with EUAs that FDA chooses to revoke because the section 564(c) criteria are no longer met or because other circumstances make such revocation appropriate to protect the public health or safety
  • 564A current good manufacturing practice deviations

Guidance transition guidance

• Devices that fall within enforcement policies listed in guidance
• FDA may add or remove guidances from this list, as appropriate
• FDA intends to remove guidances from the list if they are withdrawn
• “Policy for Diagnostic Tests for COVID-19” guidance is outside scope
Guiding Principles

- Orderly, transparent transition
- Patient and Healthcare Provider access
- Risk-based approach
- FDA action when needed
Transition is generally aligned across both guidances

Devices with issued EUAs

Devices that fall within enforcement policies

Implementation date, based on end of PHE * 
Transition period
End of phased transition

* If guidance is finalized before PHE expiration, upon PHE expiration

If guidance is finalized after PHE expiration, announce a date that is at least 45 days after the finalization of the guidance
Transition is generally aligned across both guidances

Beginning of 180-day transition

+ 90 Days: Notification of intent for certain life supporting/life sustaining devices

+ 180 Days: FDA expects manufacturers to comply with statutory and regulatory requirements applicable to their devices

Final FDA action
When distribution is not intended to continue beyond transition

<table>
<thead>
<tr>
<th>Category</th>
<th>Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUDs, non LS/LS</td>
<td>- Remain distributed and consumed</td>
</tr>
<tr>
<td>Reusable, non LS/LS</td>
<td>- Remain distributed and used if they are:</td>
</tr>
<tr>
<td></td>
<td>- Restored to cleared/approved version, <strong>OR</strong></td>
</tr>
<tr>
<td></td>
<td>- Have labeling publicly available that describes features and that device</td>
</tr>
<tr>
<td></td>
<td>lacks FDA clearance or approval</td>
</tr>
<tr>
<td>Reusable, LS/LS</td>
<td>- Remain distributed and used if they are:</td>
</tr>
<tr>
<td></td>
<td>- Restored to cleared/approved version, <strong>OR</strong></td>
</tr>
<tr>
<td></td>
<td>- Have both publicly available and a physical copy of labeling that</td>
</tr>
<tr>
<td></td>
<td>describes features and that device lacks FDA clearance or approval</td>
</tr>
<tr>
<td>IVDs under EUA</td>
<td>- Remain distributed for 2 years or until the expiration date, whichever is</td>
</tr>
<tr>
<td></td>
<td>less</td>
</tr>
</tbody>
</table>

SUD = single-use device; LS/LS = life supporting/life sustaining; IVD = In Vitro Diagnostics
Actions recommended when transition begins

**Beginning of 180-day transition**

- Transition begins on implementation date or date of advance notice of termination

+ 90 Days: Notification of intent for certain LS/LS devices

+ 180 Days: FDA expects manufacturers to comply with statutory and regulatory requirements applicable to their devices

Final FDA action

Manufacturers should submit any adverse event reports that were stored

Manufacturers should begin to prepare marketing submissions if they intend to continue distribution after transition
Actions recommended within 90 days after transition begins

Beginning of 180-day transition

+ 90 Days: Notification of intent for certain LS/LS devices

+ 180 Days: FDA expects manufacturers to comply with statutory and regulatory requirements applicable to their devices

Final FDA action

For devices that fall within applicable enforcement policies:
Follow 21 CFR Part 806 (reports of corrections and removals) and Part 807 Subparts B-D (registration and listing)

Notification of intent for certain life supporting and life sustaining devices

CFR = Code of Federal Regulations
## FDA resource planning through notification of intent for certain devices

<table>
<thead>
<tr>
<th><strong>Device types</strong></th>
<th><strong>How and when to submit</strong></th>
<th><strong>Information requested</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• List of procodes in guidances</td>
<td>• By 90 days after transition period begins</td>
<td>• General info</td>
</tr>
<tr>
<td>• Ventilator and ventilator accessories, anesthesia gas machines, other respiratory devices</td>
<td>• Send to Document Control Center</td>
<td>• EUA and other submission numbers</td>
</tr>
<tr>
<td>• Ultimately, final guidance will identify product codes for which FDA is requesting this information</td>
<td>• Cover letter should reference any FDA submission numbers</td>
<td>• Model numbers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Future plans to submit marketing submission</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Future plans to discontinue distribution, restore or relabel, and other efforts to address or mitigate risk of distributed devices</td>
</tr>
</tbody>
</table>
Actions recommended within 180 days after transition begins

Beginning of 180-day transition

+ 90 Days: Notification of intent for certain LS/LS devices

+ 180 Days: FDA expects manufacturers to comply with statutory and regulatory requirements applicable to their devices

Final FDA action

- EUA declarations are terminated and FDA withdraws enforcement policies

- Manufacturers must comply with all applicable requirements

- Marketing submissions should have already been submitted to and accepted by FDA, including Transition Implementation Plan
  - Enforcement policy for marketing submissions during FDA review before final FDA action

+ 90 Days: Notification of intent for certain LS/LS devices

+ 180 Days: FDA expects manufacturers to comply with statutory and regulatory requirements applicable to their devices

Final FDA action
Transition Implementation Plan will help guide consistent FDA-manufacturer interactions

<table>
<thead>
<tr>
<th>Estimated number of devices in distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefit-risk based plan, in event of negative decision</td>
</tr>
<tr>
<td>• Estimated number of devices in distribution</td>
</tr>
<tr>
<td>• Benefit-risk based plan for disposition if negative decision</td>
</tr>
<tr>
<td>• Notification to stakeholders of regulatory status</td>
</tr>
<tr>
<td>• Process and timeline for restoring device or relabeling</td>
</tr>
<tr>
<td>• Maintenance plan</td>
</tr>
</tbody>
</table>

| Explanation of plans for addressing already distributed product in event of positive decision |
| • Notification to stakeholders of regulatory status |
| • Process and timeline for relabeling or updates |
FDA expects compliance with applicable requirements upon final FDA actions

Beginning of 180-day transition

+ 90 Days: Notification of intent for certain LS/LS devices

+ 180 Days: FDA expects manufacturers to comply with statutory and regulatory requirements applicable to their devices

Final FDA action

FDA expects distribution to cease when:

- Marketing submission not accepted by +180 days
- Negative decision on marketing submission
- Marketing submission withdrawn or fails to provide complete response to request for additional information

FDA may take regulatory action as appropriate to protect public health
Scenarios not addressed in guidances: Please reach out to FDA to discuss

- Timeframes and actions described in guidance generally apply
- Manufacturers may wish to initiate discussions with FDA through the Q-Submission Program
- Manufacturers are expected to work toward submission of a marketing application on specific timeline
  - Note that FDA intends to help facilitate this
Example: Telethermographic System

A new telethermographic system that was not 510(k)-cleared and falls within the Enforcement Policy for Telethermographic Systems

<table>
<thead>
<tr>
<th>Phase 1 (July 1)</th>
<th>Phase 2 (September 29)</th>
<th>Phase 3 (December 28)</th>
</tr>
</thead>
</table>
| • All manufacturers continue to comply with the requirements that were not addressed in the enforcement policy, regardless of whether they intend to distribute their devices beyond the COVID-19 PHE | • **Manufacturer who intends to distribute beyond PHE:**  
  • Registers and lists and submits a marketing submission, which is accepted by the Agency  
  • **Manufacturer who does not intend to distribute beyond PHE:**  
  • Ceases distribution during Phase 2 and notifies users of regulatory status  
  • Continues to report adverse events | • Guidance document is withdrawn  
• **Manufacturer who intends to distribute beyond PHE:** FDA does not intend to object to continued distribution until FDA takes a final action. Manufacturer receives an NSE decision after review and ceases distribution. FDA and manufacturer engage to address already-distributed devices  
• **Manufacturer who does not intend to distribute beyond PHE:** Manufacturer leaves previously distributed devices in field and makes revised labeling publicly available, sends notices to users, and continues to report adverse events |
**Example: Continuous Ventilator**

A continuous ventilator was authorized under the umbrella EUA for ventilators.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>July 1</td>
<td>• Advance notice of termination of the relevant EUA declaration is published in the Federal Register</td>
</tr>
<tr>
<td>August 1</td>
<td>• Manufacturer submits a Notification of Intent to inform FDA that it does not intend to pursue a marketing authorization</td>
</tr>
</tbody>
</table>
| January 1  | • Relevant EUA declaration is terminated and the umbrella EUA is no longer in effect  
• Manufacturer ceases distribution of the device  
• FDA does not intend to object if the manufacturer develops a plan for the already distributed product to remain distributed |
Providing Comment on Draft Guidances
A Note about Draft Guidances

• You may comment on any guidance at any time
  – see 21 CFR 10.115(g)(5)

• Please submit comments on draft guidance before closure date
  – to ensure that FDA considers your comment on a draft guidance before we work on final guidance
Submit Comments to Dockets by: March 23, 2022

• Draft Guidance: Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency
  • Docket: FDA-2021-D-1118 (www.regulations.gov/docket/FDA-2021-D-1118)
  • Guidance

• Draft Guidance: Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency
  • Docket: FDA-2021-D-1149 (www.regulations.gov/docket/FDA-2021-D-1149)
  • Guidance
Summary

• FDA has proposed a transition plan for devices with issued EUAs or that fall within enforcement policies during the COVID-19 PHE

• FDA invites stakeholder feedback now while the COVID-19 PHE is ongoing

• The transition guidances propose actions and milestones to support FDA and stakeholders through a transparent and orderly transition

• FDA requests stakeholder feedback by March 23, 2022
Let’s Take Your Questions

• **To Ask a Question:**
  1. Please “Raise Your Hand”
  2. Moderator will Announce Your Name to Invite You to Ask Your Question
  3. Unmute yourself when called

• **When Asking a Question:**
  • Ask 1 question only
  • Keep question short
  • No questions about individual submissions

• **After Question is Answered:**
  • Please mute yourself again
  • If you have more questions - raise your hand again
Thanks for Joining Today!

• Presentation and Transcript will be available at CDRH Learn:
  •  www.fda.gov/Training/CDRHLearn

• Additional questions about today’s presentation
  •  Email: DICE@fda.hhs.gov

• Give Us Your Feedback!
  •  www.fda.gov/CDRHWebinar

• Upcoming Webinars